Table 2 Correlation of cytoplasmic actinin-4 expression with clinicopathological parameters in advanced-stage ovarian cancers
Number of cases (%) | ||||
|---|---|---|---|---|
Cytoplasmic/membrane immunoreactivity | ||||
Factor | Total | High (n=82) | Low (n=54) | P-value |
Age, years (median±s.d.) | 56.0 (±11.2) | 552 (±10.1) | 0.677 | |
FIGO a stage | 0.205 | |||
III | 103 | 59 (57) | 44 (43) | |
IV | 33 | 23 (70) | 10 (30) | |
Residual tumor (cm) | 0.0033 | |||
<1 | 43 | 18 (42) | 25 (58) | |
≧1 | 92 | 63 (68) | 29 (32) | |
Unknown | 1 | 1 | ||
Histological grade | 0.056 | |||
1 or 2 | 93 | 51 (55) | 42 (45) | |
3 | 43 | 31 (72) | 12 (28) | |
Histological type | 0.126 | |||
Serous | 91 | 59 (65) | 32 (35) | |
Clear cell | 25 | 13 (52) | 12 (48) | |
Endometrioid | 10 | 3 (30) | 7 (70) | |
Mucinous | 10 | 7 (70) | 3 (30) | |
Lymph node metastasis | 0.111 | |||
Absent | 20 | 7 (35) | 13 (65) | |
Present | 33 | 19 (58) | 14 (42) | |
Response to chemotherapies | 0.070 | |||
Complete response/partial response | 54 | 33 (61) | 21 (39) | |
Stable disease/progressive disease | 38 | 30 (79) | 8 (21) | |
5-Year survival (%) | 37.4 | 51.6 | 0.089b | |
